Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Psoriasis 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dermatitis 1

Interventions

Cyclophosphamide 146Rituximab 138fludarabine phosphate 111Mycophenolic Acid 69Peripheral Blood Stem Cell Transplantation 63fludarabine 59Tacrolimus 58Whole-Body Irradiation 51venetoclax 46Busulfan 46ibrutinib 45Cyclosporine 42Lenalidomide 41Filgrastim 41Alemtuzumab 41Melphalan 40Radiotherapy 39obinutuzumab 37Antilymphocyte Serum 35Etoposide 33Methotrexate 32ofatumumab 29acalabrutinib 26Bendamustine Hydrochloride 24sargramostim 22Methylprednisolone 18Cytarabine 18zanubrutinib 17Pentostatin 17Granulocyte Colony-Stimulating Factor 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphocytic, Chronic, B-Cell × sotrastaurin × Clear all
NCT02285244 2017-04-05

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡